Talcum Powder Cancer Lawsuit

MDL Judge Freda Wolfson Will Not Decide LTL Management's New Jersey Bankruptcy Fate

New Jersey bankruptcy judge will decide if and when trials that are suspended may resume

Monday, January 17, 2022 - Chief U.S. District Judge Freda Wolfson is presiding over tens of thousands of ovarian cancer lawsuits organized into multidistrict litigation (MDL) because of their similarities. The judge recently told plaintiffs who have had their talcum powder lawsuits suspended temporarily that they will have to wait until the bankruptcy judge in New Jersey makes a critical decision at the end of this month. According to Reuters, "U.S. Bankruptcy Judge Michael Kaplan, who oversees the LTL bankruptcy (LTL Management LLC), issued a temporary order shielding J&J from litigation, which expires on Jan. 28." Judge Kaplan has been given about 30 days until the end of January to get up to speed with the controversial legal maneuver called the Texas Two-Step TTS) The TTS allows large multi-faceted corporations to spin off part of the company, presumably the one that is in trouble, into a separate business entity, and then file for bankruptcy. The move shields the parent company from the legal liabilities of failing to provide customers with an adequate talcum powder cancer warning. In the case of Johnson & Johnson, the company put the legal liabilities stemming from their talcum powder allegedly causing ovarian cancer into a separate company along with $2 billion. Johnson & Johnson has discontinued selling their iconic baby powder in North America but continues to make billions of dollars selling it throughout Asia and India. It would seem natural for the New Jersey judge to force Johnson & Johnson to include all Johnson's Baby Powder sales in the bankruptcy and then force the company to sell the assets bringing tens of billions of dollars into the trust. The money could then be used to fund an adequate settlement agreement rather than force ovarian cancer victims to settle for pennies on the dollar. The group that sought a decision on the length of the trial suspensions thought that the New Jersey MDL judge would be more qualified to render a decision because of her familiarity with the Johnson's Baby Powder Ovarian Cancer cases. Judge Wolfson conducted Daubert hearings on the matter a couple of years ago and hear scientific testimony from both sides. The judge then deliberated and investigated for six months before deciding on which scientific expert witnesses would be permitted to testify, and which ones did not hold water. At the heart of the science is whether talc itself can cause ovarian cancer. One expert who thinks so told the judge that particles of talc can enter the vagina, travel through the Fallopian tubes, and become permanently lodged in the ovaries, the dead-end of the female reproductive system. Judge Wolfson said she will give her written opinion to New Jersey bankruptcy Judge Kaplan by January 21 to help him decide on the bankruptcy matter.

It does not appear likely that Johnson & Johnson will be permitted to file for bankruptcy in the newly formed company unless their entire talcum powder business is included, at the very least. That is what happened to Imreys Inc., the sole talc supplier to Johnson & Johnson. The company declared their North American mining operation bankrupt, sold them for a couple of hundred of million dollars to Magriss Inc., and put the proceeds into a trust to pay Johnson's Baby powder cancer victims.

Information provided by TalcumPowderCancerLawsuit.com, a website devoted to providing news about talcum powder ovarian cancer lawsuits, as well as medical research and findings.

More Recent Talcum Powder Ovarian Cancer Lawsuit News:

View all Talcum Powder Cancer Lawsuit News

No-Cost, No-Obligation Baby Powder Lawsuit Case Review for Persons or Families of Persons Who Developed Ovarian Cancer After a History of Perineal Baby Powder Use

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.

Privacy Notice: This site uses cookies for advertising, analytics and to improve our site services. By continuing to use our site, you agree to our use of cookies. For more information, see our cookie and privacy policy.